I was just reading through Mason14's paper (which as many have stated, I also think is a great piece of work) and it raised a question around preclinical/ clinical trial design, and if it is common practise to involve a, or several, large pharma companies in the process?
Without discussing RAC specifically, I was wondering if Dr. T might shed any light on whether to his knowledge, this is common practise in such instances?
Equally, is there a consultation process with the FDA and other governing bodies around trial design, or are they simply presented with a road map once the company has finalised it?
Again, I'm not looking for info on RAC, more a better understanding of common practise.
Apologies if this has been covered.
RAC Primer, page-176
-
- There are more pages in this discussion • 346 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |